Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
1999-03-31
2001-05-22
Yucel, Remy (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S006120, C435S091100, C435S375000, C435S325000, C435S366000, C536S023100, C536S024300
Reexamination Certificate
active
06235891
ABSTRACT:
FIELD OF THE INVENTION
This invention relates generally to compositions and methods for enhancing glucocorticoid therapy and for enhancing the inhibition of hyperproliferation of cells, and more particularly to a composition comprising a glucocorticoid receptor agonist and a compound which decreases levels of active human serine/threonine protein phosphatase 5 in cells.
BACKGROUND OF THE INVENTION
Throughout this application various publications are referenced, many in parenthesis. Full citations for each of these publications are provided at the end of the Detailed Description. The disclosures of each of these publications in their entireties are hereby incorporated by reference in this application.
Abnormal proliferative or hyperproliferative conditions include hypoproliferative disorders such as cancer, tumors and hyperplasias, including smooth muscle cell proliferation in the blood vessels (such as stenosis or restenosis following angiopathy). In these conditions, a means to control or inhibit (decrease) hyperproliferation is desirable. Many types of cellular mechanisms/molecules have been or could be associated with regulation of cellular proliferation. For example, the reversible phosphorylation of proteins on serine and threonine residues is a major intracellular control mechanism that regulates cell proliferation. The phosphorylation state of a protein is controlled by kinases, which phosphorylate proteins, and phosphatases, which dephosphorylate proteins. A number of families and types of protein phosphatases exist, including tyrosine phosphatases and serine/threonine protein phosphatases (PPs). An increase in expression of certain PPs has been described in several tumor types. Therefore, one could speculate that inhibitors of PP expression may have an effect on tumors (such as an anti-proliferative effect).
Small molecule inhibitors of protein phosphatases have been used to study PP function. The best characterized of these is okadaic acid, which is the causative agent of diarrhetic shellfish poisoning. It is a potent inhibitor of PP2A and PP1 and a much (roughly a thousandfold) less potent inhibitor of PP2B. Other inhibitors of one or more PPs include tautomycin, cyclosporin A, dinophysistoxin, calyculin, microcystin, nodularin and cantharidin (Cairns et al. 1994; Wera and Hemmings 1995).
One could also speculate that antisense oligonucleotides could be used to inhibit PP expression. Antisense oligonucleotides have been safely administered to humans and clinical trials of several antisense oligonucleotide drugs, targeted both to viral and cellular gene products, are presently underway.
In addition to the role of PPs in cell proliferation, glucocorticoids are another example of a cellular molecule which has been associated with cellular proliferation. Glucocorticoids are known to induce growth arrest in the G1-phase of the cell cycle in a variety of cells, both in vivo or in vitro, and have been shown to be useful in the treatment of certain cancers. The glucocorticoid receptor (GR) belongs to an important class of transcription factors that alter the expression of target genes in response to a specific hormone signal. Accumulated evidence indicates that receptor associated proteins play key roles in regulating glucocorticoid signaling. The list of cellular proteins that can bind and co-purify with the GR is constantly expanding. PP5 has been shown to be one of the proteins that co-immunoprecipitated with GR (Chen et al, 1996).
These two, PP5 and glucocorticoids, are merely two examples of many cellular mechanisms/molecules which have been associated with regulation of cellular proliferation. A need continues to exist to elucidate further means to regulate cell proliferation, in particular to decrease cell proliferation in hyperproliferative disorders.
Glucocorticoids are also used for their anti-inflammatory effect on the skin, joints, and tendons. They are important for treatment of disorders where inflammation is thought to be caused by immune system activity, such as rheumatoid arthritis, inflammatory bowel disease, glomerulonephritis, and connective tissue diseases like systemic lupus erythmatosus. They are used to treat asthma and are widely used with other drugs to prevent the rejection of organ transplants. Some cancers of the blood (leukemias) and lymphatic system (lymphomas) may also respond to corticosteroid drugs. A method of enhancing the beneficial effects of glucocorticoid therapy in these instances would always be desirable.
SUMMARY OF THE INVENTION
The subject invention addresses these needs by providing a composition comprising a glucocorticoid receptor agonist and a compound which decreases levels of active human serine/threonine protein phosphatase 5 protein in cells. Preferably, the compound which decreases levels of active (functional) human serine/threonine protein phosphatase 5 protein in cells is an antisense oligonucleotide targeted to a nucleic acid encoding human serine/threonine protein phosphatase 5. The composition of the subject invention can be used to enhance glucocorticoid therapy and to enhance the inhibition of hyperproliferation of cells. In one embodiment, the composition is used in a method of enhancing glucocorticoid activity in cells which comprises contacting cells with an amount of the composition of the subject invention effective to enhance glucocorticoid activity in the cells. In another embodiment, the composition is used in a method of enhancing the inhibition of hyperproliferation of cells, wherein the inhibition is by contacting the cells with a compound which decreases levels of active human serine/threonine protein phosphatase 5 protein in cells, which method comprises contacting the cells with an amount of the composition of the subject invention effective to enhance the inhibition of hyperproliferation of the cells. The composition of the subject invention can thus be used to enhance glucocorticoid therapies in conditions such as inflammations and asthma, and to enhance therapy in hyperproliferative disorders such as cancer based on decreasing levels of active PP5.
REFERENCES:
patent: 5034506 (1991-07-01), Summerton et al.
patent: 5138045 (1992-08-01), Cook et al.
patent: 5218105 (1993-06-01), Cook et al.
patent: 5225326 (1993-07-01), Bresser et al.
patent: 5459255 (1995-10-01), Cook et al.
patent: 5591721 (1997-01-01), Agrawal et al.
patent: 5767113 (1998-06-01), Cohn et al.
patent: WO 92/20823 (1992-11-01), None
patent: WO 99/27134 (1999-06-01), None
patent: WO 99/27136 (1999-06-01), None
Branch, TIBS 23, pp. 45-50, Feb. 1998.*
Flanagan et al, Nature Biotech 17:48-52, Jan. 1999.*
Zuo et al, J. Biol Chem 273 (20) pp. 12250-12258, May 15, 1998.*
Tian et al, J. Biol Chem 273 (22) pp. 13531-13536, May 29, 1998.*
Agarwal, M.L., et al., Proc Natl Acad Sci USA 92:8493-8497 (1995).
Ammala, C., et al., Proc Natl Acad Sci USA 91:4343-4347 (1994).
Bastians, H., et al., J Cell Sci 109:2865 (1996).
Bialojan, A., et al., Biochem J 256:283 (1988).
Brewis, N.D., et al., EMBO J 12:987 (1993).
Cairns, J., et al., J of Bio Chem 269(12):9176-9183 (1994).
Chen, M.X., et al., EMBO J 13(18):4278-4290 (1994).
Chernova, O. B., et al., Trends Bio Sci 20:431 (1995).
Cohen, P., Annu Rev Biochem 58:453 (1989).
Cohen, P., et al., FEBS Lett 268:355 (1990).
Cohen, P., et al., Trends Bio Sci 15:98 (1990).
Cohen, P., TIBS 22: 245-251 (1997).
Duttaroy, A., et al., J Cell Biochem 64:434 (1997).
Dynlacht, B.D., Nature 389:149 (1997).
Egloff, M.P. et al., J Mol Biol 254:942 (1995).
Elledge, S.J., et al., Curr Opin Cell Biol 6:847 (1994).
Gomyo, Y., et al., Cancer 79:2067 (1997).
Gottlieb, T.M., et al., Biochem Biophys Acta 1287:77 (1996).
Gu., Y., et al., Nature 366:707 (1993).
Harper, J.W., et al., Mol Biol Cell 6:387 (1995).
Honkanen, R.E., et al., J Biol Chem 265:19401 (1990).
Honkanen, R.E., et al., Toxicon 32:339 (1994).
Hsiao, M., et al., Biochem Biophys Res Commun 233:329 (1997).
Hunter, T., et al., Cell 79:573 (1994).
Lamb, J.R., et al., Trends in Bio Sci 20:257 (1995).
Macleod, K.F., et al., Genes Dev 9:935 (1995).
Peter, M., et al., Ce
Braman & Rogalskyj LLP
Schmidt M
South Alabama Medical Science Foundation
Yucel Remy
LandOfFree
Glucocorticoid receptor agonist and decreased PP5 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glucocorticoid receptor agonist and decreased PP5, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glucocorticoid receptor agonist and decreased PP5 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2496056